^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Gastroesophageal Junction Adenocarcinoma |
| Drug: | AZD0901 (Microtubule inhibitor, CLDN18.2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Connoya CMG901 Receives FDA Fast Track Designation for Relapsed/Refractory Gastric Cancer and Gastroesophageal Junction Adenocarcinoma
Published date:
04/19/2022
Excerpt:
Keymed Biosciences...announced that the U.S. Food and Drug Administration (FDA) granted CMG901 Fast Track Designation as monotherapy for the treatment of unresectable or metastatic gastric and gastroesophageal junction cancer which have relapsed and/or are refractory to approved therapies.
